Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-18 Armored STEAP1 CAR T in mCRPC
NCT07803653Phase 1Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FH-STEAP1 IL-18 CAR T cells in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Treatment-related unexpected grade 3 or higher toxicity at 28 days, Incidence of adverse events at 28 days and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
FH-STEAP1 IL-18 CAR T cells
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07803653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803653.